மணி ஆரோக்கியம் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மணி ஆரோக்கியம் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மணி ஆரோக்கியம் இன்க் Today - Breaking & Trending Today

Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.


Press release content from Business Wire. The AP news staff was not involved in its creation.
Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.
May 15, 2021 GMT
TORONTO (BUSINESS WIRE) May 15, 2021
Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities class action on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. (“Bellus” or “Company”)
(NASDAQ: BLU, TSX: BLU, FWB: BHN0) from September 5, 2019 through July 5, 2020, inclusive (the “Class Period”). ....

New York , United States , Manjit Singh , Kim Spencer Mcphee , Bellus Or Company , Morganti Co , Nasdaq Or Toronto Stock Exchange , Bellus Health Inc , Bellus Health , Toronto Stock Exchange , Kim Spencer Mcphee Barristers , Andrew Morganti , Business Wire , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , மன்ஜித் சிங் , கிம் ஸ்பென்சர் மக்ஃபீ , மோர்கந்தி இணை , நாஸ்டாக் அல்லது டொராண்டோ ஸ்டாக் பரிமாற்றம் , மணி ஆரோக்கியம் இன்க் , மணி ஆரோக்கியம் , டொராண்டோ ஸ்டாக் பரிமாற்றம் , கிம் ஸ்பென்சர் மக்ஃபீ பாரிஸ்டர்கள் , வணிக கம்பி ,

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Bellus Health, Inc. and Encourages Investors to Contact the Firm


DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Bellus Health, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Bellus Health, Inc. securities between September 5, 2019 and July 5, 2020, inclusive . Investors have until May 17, 2021 to apply to the Court to be appointed as …
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Bellus Health, Inc. (NASDAQ: BLU) securities between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”). Investo ....

New York , United States , South Carolina , Brandon Walker , Bragar Eagel Squire , Melissa Fortunato , Marion Passmore , United States District Court , Bellus Health Inc , Bragar Eagel , Southern District , Bellus Health , Class Period , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கரோலினா , பிராண்டன் வாக்கர் , மெலிசா அதிர்ஷ்டம் , மரியன் பாஸ்மோர் , ஒன்றுபட்டது மாநிலங்களில் மாவட்டம் நீதிமன்றம் , மணி ஆரோக்கியம் இன்க் , தெற்கு மாவட்டம் , மணி ஆரோக்கியம் , வர்க்கம் காலம் ,

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BELLUS Health Inc. - BLU


NEW YORK, May 13, 2021 /PRNewswire/  Pomerantz LLP is investigating claims on behalf of investors of
 BELLUS Health Inc. ( BELLUS or the Company ) (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 
- Advertisement -
On July 6, 2020, Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough.  Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked.  Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.  ....

New York , United States , France General , Los Angeles , Abrahaml Pomerantz , Roberts Willoughby , Pomerantz Firm , Bellus Health Inc , Nasdaq Nms Blu , New York , North East , United States Of America , North America , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , லாஸ் ஏஞ்சல்ஸ் , ராபர்ட்ஸ் விருப்பம் , போமேரதண்தஜ் நிறுவனம் , மணி ஆரோக்கியம் இன்க் ,

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BELLUS Health Inc.


Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/  Pomerantz LLP is investigating claims on behalf of investors of
 BELLUS Health Inc. ( BELLUS or the Company ) (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 
On July 6, 2020, Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough.  Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked.  Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.  ....

New York , United States , France General , Los Angeles , Abrahaml Pomerantz , Roberts Willoughby , Pomerantz Firm , Bellus Health Inc , Pomerantz Llp , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , லாஸ் ஏஞ்சல்ஸ் , ராபர்ட்ஸ் விருப்பம் , போமேரதண்தஜ் நிறுவனம் , மணி ஆரோக்கியம் இன்க் , போமேரதண்தஜ் ல்ப் ,